Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

NantKwest

Founders Patrick Soon-Shiong

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$18M
Portfolio companies 1
Rounds per year 0.05
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Therapeutics
  • Biopharma
  • Pharmaceutical
  • Biotechnology
  • Medical
Summary

In 2002 was created NantKwest, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the San Diego. The fund was located in North America if to be more exact in United States.

The typical case for the fund is to invest in rounds with 4 participants. Despite the NantKwest, startups are often financed by Lilly Ventures, Forward Ventures, DeNovo Ventures. The meaningful sponsors for the fund in investment in the same round are Wicklow Capital, Latterell Venture Partners, Forward Ventures. In the next rounds fund is usually obtained by Taiwania Capital, SalubrisBio.

The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars.

Among the most successful fund investment fields, there are Biotechnology, Biopharma. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Viracta Therapeutics

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of NantKwest:
Typical Co-investors
NantKwest is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after NantKwest:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Harbert Growth Partners Richmond, United States, Virginia
Motorola Chicago, Illinois, United States
Penny Lane Advisors -
RTI International North Carolina, Raleigh, United States
Sidus Investment Management New York, New York, United States
Suzhou Hengchuang Touzi China, Jiangsu, Suzhou
Vital Venture Capital Bethesda, Maryland, United States
Zee Entertainment Enterprises India, Maharashtra, Mumbai
Zhuhai Gree Financial Investment Management -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Viracta Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
Therapeutics
$18M04 Apr 2017 California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent NantKwest?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 18M
Rounds per year 0.05
Peak activity year 2017
Lead investments 1
Exits 1
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Viracta Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
Therapeutics
$18M04 Apr 2017 California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: